Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by 2034 | DelveInsight [Yahoo! Finance]
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Sonnet BioTherapeutics regains compliance with Nasdaq [Seeking Alpha]